Loading
companiesCompany
Leaps by Bayer
Bayer's impact investing unit, which funds companies tackling ten 'leaps' in health and agriculture, including curing cancer. Its website blocked automated access at the time of research.
Overview
Leaps by Bayer is the impact investment unit of Bayer AG that backs early-stage companies pursuing large 'leaps' in health and agriculture; one of its stated leaps concerns cancer, and it has invested in cell therapy and precision oncology start-ups. Its website (leaps.bayer.com) and the Leaps page on bayer.com both returned HTTP 403 with a 'Site Maintenance' bot-blocking message on every attempt, so the unit's own description, founding year, location and named oncology portfolio companies could not be confirmed from a primary source.
Portfolio (2)
Filter the startups table| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Affini-T Therapeutics Watertown, MA, US | Startup | cell therapy | Form D offering 2024, $18M | |
| Century Therapeutics Philadelphia, PA, US | Public | cell therapy | none on record |
Notes
top- Website could not be fetched by the research pass on 2026-09-10 (bot protection, JavaScript-only or parked domain); location and description rest on the firm's public materials and on press releases that name it. leaps.bayer.com and bayer.com returned 403 bot-block pages via curl and WebFetch. Berlin follows the task hint (Bayer's pharmaceuticals division is based in Berlin; the group HQ is Leverkusen).